Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk (NCT04774159)
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk: A Randomized Trial
🩺 Plain-English Summary (8th-Grade Level)
The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.
Who can join: Review the eligibility criteria below.
Location: Yale School of Medicine — New Haven, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (70 Sites)
Showing the first 25 of 70 sites.
- Yale School of Medicine — New Haven, Connecticut
- University of Florida - Gainesville — Gainesville, Florida
- Tampa General Hospital — Tampa, Florida
- University of Chicago Medical Center — Chicago, Illinois
- Henry Ford Health System — Detroit, Michigan
- Mayo Clinic — Rochester, Minnesota
- Rutgers University — Newark, New Jersey
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Duke Regional Hospital — Durham, North Carolina
- Duke University Medical Center — Durham, North Carolina
- Duke Raleigh Hospital — Raleigh, North Carolina
- Ohio State University Wexner Medical Center — Columbus, Ohio
- Vanderbilt University Medical Center — Nashville, Tennessee
- Southwest Family Medicine — Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- Texas Tech University Health Sciences — Lubbock, Texas
- Sentara Norfolk General Hospital — Norfolk, Virginia
- University of Washington Medical Center — Seattle, Washington
- Medical College of Wisconsin — Milwaukee, Wisconsin
- Sir Charles Gairdner Hospital — Perth, Western Australia
- Universitair Ziekenhuis Leuven — Leuven,
- Clínica Procárdio — Blumenau, Santa Catarina
- Sociedade Hospitalar Angelina Caron — Campina Grande do Sul,
- Hospital Universitário (CoraCentro Pesquisa Clinica) — Canoas,
- Incore — Dois Vizinhos,
📞 Contact the Study Coordinator
Phone: (905) 521-2100
Email: Noel.Chan@TAARI.CA
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Peripheral Arterial Disease
- SELUTION4SFA Trial — Little Rock, Arkansas
- SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs — New Haven, Connecticut
- A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND) — Birmingham, Alabama
- Shortwave Diathermy In-home Treatment for Indianapolis VA-only Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy — Indianapolis, Indiana
- FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease — Chicago, Illinois
- MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology — Omaha, Nebraska
Explore by condition: All Peripheral Arterial Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.